297 related articles for article (PubMed ID: 25274276)
21. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
22. [CCAFU Recommendations 2013: Renal cancer].
Patard JJ; Baumert H; Bensalah K; Bernhard JC; Bigot P; Escudier B; Grenier N; Hétet JF; Long JA; Méjean A; Paparel P; Richard S; Rioux-Leclercq N; Coloby P; Soulié M;
Prog Urol; 2013 Nov; 23 Suppl 2():S177-204. PubMed ID: 24485292
[TBL] [Abstract][Full Text] [Related]
23. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
Uhlig A; Uhlig J; Trojan L; Woike M; Leitsmann M; Strauß A
Future Oncol; 2021 Jan; 17(1):45-56. PubMed ID: 33275038
[TBL] [Abstract][Full Text] [Related]
24. Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.
Rothermundt C; Bailey A; Cerbone L; Eisen T; Escudier B; Gillessen S; Grünwald V; Larkin J; McDermott D; Oldenburg J; Porta C; Rini B; Schmidinger M; Sternberg C; Putora PM
Oncologist; 2015 Sep; 20(9):1028-35. PubMed ID: 26240132
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
26. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
27. Renal cell carcinoma: presentation, staging, and surgical treatment.
Russo P
Semin Oncol; 2000 Apr; 27(2):160-76. PubMed ID: 10768595
[TBL] [Abstract][Full Text] [Related]
28. The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.
Bigot P; Lebdai S; Ravaud A; Azzouzi AR; Ferrière JM; Patard JJ; Bernhard JC
World J Urol; 2013 Dec; 31(6):1383-8. PubMed ID: 23542915
[TBL] [Abstract][Full Text] [Related]
29. Treatment selection in metastatic renal cell carcinoma: expert consensus.
Escudier B; Szczylik C; Porta C; Gore M
Nat Rev Clin Oncol; 2012 Apr; 9(6):327-37. PubMed ID: 22473096
[TBL] [Abstract][Full Text] [Related]
30. Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Wendel C; Campitiello M; Plastino F; Eid N; Hennequin L; Quétin P; Longo R
Am J Case Rep; 2017 Jan; 18():7-11. PubMed ID: 28044054
[TBL] [Abstract][Full Text] [Related]
31. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend J; Kuczyk M
Aktuelle Urol; 2015 Mar; 46(2):151-7. PubMed ID: 25897537
[TBL] [Abstract][Full Text] [Related]
32. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Dranitsaris G; Schmitz S; Broom RJ
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
[TBL] [Abstract][Full Text] [Related]
33. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y
Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
[TBL] [Abstract][Full Text] [Related]
34. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
35. Surgical management of large renal tumors.
Wszolek MF; Wotkowicz C; Libertino JA
Nat Clin Pract Urol; 2008 Jan; 5(1):35-46. PubMed ID: 18185512
[TBL] [Abstract][Full Text] [Related]
36. Update on systemic therapies of metastatic renal cell carcinoma.
Herrmann E; Bierer S; Wülfing C
World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
[TBL] [Abstract][Full Text] [Related]
37. [Advancement in the treatment of renal carcinoma].
Méjean A
Nephrol Ther; 2017 May; 13(3):154-159. PubMed ID: 28527565
[TBL] [Abstract][Full Text] [Related]
38. [Guideline 'Renal cell carcinoma'].
Mulders PF; Brouwers AH; Hulsbergen-van der Kaa CA; van Lin EN; Osanto S; de Mulder PH
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):376-80. PubMed ID: 18380384
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
